@inproceedings{inproceedings, title  = {{Long-term efficacy and safety data for dupilumab in a phase 3, Open-Label Extension Trial (LIBERTY AD PED-OLE) in patients aged >= 6 to < 12 years with moderate-to-severe atopic dermatitis (AD)}},

 url = {{}},

 year = {{2021}},

 month = {{1}},

 author = {{Cork MJ and Thaci D and Eichenfield L and Arkwright PD and Bastian M and Chen Z and Delevry D and O'Malley JT and Bansal A}},

 volume = {{19}},

 journal = {{JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT}},

 pages = {{14-14}},

 note = {{Accessed on 2024/12/22}}}